133 related articles for article (PubMed ID: 12242723)
1. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
Bennett JJ; Delman KA; Burt BM; Mariotti A; Malhotra S; Zager J; Petrowsky H; Mastorides S; Federoff H; Fong Y
Cancer Gene Ther; 2002 Nov; 9(11):935-45. PubMed ID: 12386832
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
5. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
7. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
10. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
11. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
13. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
15. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
16. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
[TBL] [Abstract][Full Text] [Related]
17. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
Miyatake SI; Tani S; Feigenbaum F; Sundaresan P; Toda H; Narumi O; Kikuchi H; Hashimoto N; Hangai M; Martuza RL; Rabkin SD
Gene Ther; 1999 Apr; 6(4):564-72. PubMed ID: 10476216
[TBL] [Abstract][Full Text] [Related]
18. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer.
Stiles BM; Bhargava A; Adusumilli PS; Stanziale SF; Kim TH; Rusch VW; Fong Y
Surgery; 2003 Aug; 134(2):357-64. PubMed ID: 12947341
[TBL] [Abstract][Full Text] [Related]
19. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Lee CY; Bu LX; Rennie PS; Jia WW
Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
